Company Filing History:
Years Active: 2024-2025
Title: Innovations of Andreas René Rötheli
Introduction
Andreas René Rötheli is a notable inventor based in Wellesley, MA (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds related to obicetrapib. With a total of 2 patents, his work has implications for the synthesis and manufacturing processes of important pharmaceutical compounds.
Latest Patents
Rötheli's latest patents focus on the salts of obicetrapib and the processes for their manufacture. One of the key innovations includes a method for producing a compound of obicetrapib and its calcium salts. Additionally, he has developed amorphous obicetrapib hemicalcium, which is a new intermediate for the synthesis of obicetrapib. His patents also cover the creation of obicetrapib HCl and a mesylate salt, which are essential for the synthesis of obicetrapib and its amorphous form.
Career Highlights
Andreas Rötheli is currently associated with NewAmsterdam Pharma B.V., where he continues to advance his research and development efforts. His work is pivotal in the pharmaceutical industry, particularly in the area of drug formulation and synthesis.
Collaborations
Rötheli collaborates with esteemed colleagues such as Sheng Cui and Christopher J Borths, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Andreas René Rötheli's contributions to the field of pharmaceutical chemistry through his patents and collaborations highlight his role as a significant inventor. His work on obicetrapib and its derivatives showcases the importance of innovation in drug development.